BillionToOne, Inc. (BLLN): Capital Expenditures

Annual figures by period end, from SEC filings.

$8.88M

Year ended 2025-12-31

$12.18M

Trailing 12 months to 2026-06-30

2023-12-31 Capital Expenditures (USD) 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$8.88M	+64.4%	2026-03-11, From 2025-01-01
2024-12-31	$5.40M	-12.5%	2026-03-11, From 2024-01-01
2023-12-31	$6.17M	n/a	2026-03-11, From 2023-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
BillionToOne, Inc. (BLLN)	2025-12-31	$8.88M	+64.4%
Fulgent Genetics, Inc. (FLGT)	2025-12-31	$22.57M	-44.0%
Castle Biosciences Inc (CSTL)	2025-12-31	$36.02M	+27.2%
Veracyte, Inc. (VCYT)	2025-12-31	$9.68M	-14.3%
GRAIL, Inc. (GRAL)	2025-12-31	$909.0K	-82.5%
Caris Life Sciences, Inc. (CAI)	2025-12-31	$16.26M	+92.6%
Guardant Health, Inc. (GH)	2025-12-31	$48.31M	+37.7%
Biodesix Inc (BDSX)	2025-12-31	$259.0K	-92.0%
Personalis, Inc. (PSNL)	2025-12-31	$4.50M	+181.0%

Compare BLLN, FLGT, CSTL, VCYT side by side · Screen every company in Services-Medical Laboratories ↗